Lantern Pharma Inc
(LTRN)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2024 | 03-2024 | 12-2023 | 09-2023 | 06-2023 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -10,400 | -5,441 | -15,962 | -11,776 | -8,614 |
| Depreciation Amortization | -85 | -30 | -159 | -105 | -80 |
| Other Working Capital | 1,829 | 2,131 | 538 | -341 | 439 |
| Other Operating Activity | 397 | 272 | 1,235 | 1,260 | 906 |
| Operating Cash Flow | $-8,259 | $-3,069 | $-14,347 | $-10,961 | $-7,349 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -752 | -554 | -912 | -1,173 | -1,409 |
| PPE Investments | -7 | -2 | -19 | -14 | -9 |
| Investing Cash Flow | $-758 | $-556 | $-930 | $-1,186 | $-1,418 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 55 | 55 | N/A | N/A | N/A |
| Common Stock Repurchased | N/A | N/A | -500 | N/A | N/A |
| Financing Cash Flow | $55 | $55 | $-500 | $N/A | $N/A |
| Exchange Rate Effect | 2 | -10 | -29 | -24 | -11 |
| Beginning Cash Position | 21,938 | 21,938 | 37,743 | 37,743 | 37,743 |
| End Cash Position | 12,977 | 18,358 | 21,938 | 25,572 | 28,964 |
| Net Cash Flow | $-8,961 | $-3,580 | $-15,805 | $-12,171 | $-8,779 |
| Free Cash Flow | |||||
| Operating Cash Flow | -8,259 | -3,069 | -14,347 | -10,961 | -7,349 |
| Capital Expenditure | -7 | -2 | -19 | -14 | -9 |
| Free Cash Flow | -8,266 | -3,071 | -14,365 | -10,975 | -7,358 |